



Accurate Identification of *ALK* Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence *In Situ* Hybridization Scanning System and Ultrasensitive Immunohistochemistry

Esther Conde¹, Ana Suárez-Gauthier¹, Amparo Benito², Pilar Garrido², Rosario García-Campelo³, Michele Biscuola⁴, Luis Paz-Ares⁴, David Hardisson⁵, Javier de Castro⁵, M. Carmen Camacho⁶, Delvys Rodriguez-Abreu⁶, Ihab Abdulkader⁷, Josep Ramirez⁸, Noemí Reguart⁸, Marta Salido⁹, Lara Pijuán⁹, Edurne Arriola⁹, Julián Sanz¹⁰, Victoria Folgueras¹¹, Noemí Villanueva¹¹, Javier Gómez-Román¹², Manuel Hidalgo¹³, Fernando López-Ríos^{1*}

1 Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico “Clara Campal”, Hospital Universitario Madrid Sanchinarro, Universidad San Pablo-CEU, Madrid, Spain, **2** Hospital Ramón y Cajal, Madrid, Spain, **3** C.H.U. A Coruña, La Coruña, Spain, **4** Hospital Virgen del Rocío, Sevilla, Spain, **5** IdiPAZ (Hospital La Paz Institute for Health Research), University Hospital La Paz, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain, **6** Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, **7** C.H.U. Santiago de Compostela, Santiago de Compostela, Spain, **8** Hospital Clinic, Barcelona, Spain, **9** Hospital del Mar-Parc de Salut Mar, Barcelona, Spain, **10** Hospital Clínico San Carlos, Madrid, Spain, **11** Hospital Central de Asturias, Oviedo, Spain, **12** Hospital Marqués de Valdecilla, Santander, Spain, **13** Oncology Department, Centro Integral Oncológico “Clara Campal”, Hospital Universitario Madrid Sanchinarro, Universidad San Pablo-CEU, Madrid, Spain

Abstract

Background: Based on the excellent results of the clinical trials with *ALK*-inhibitors, the importance of accurately identifying *ALK* positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC. The controversy is further fuelled by the different regulatory approvals. This situation prompted us to investigate two *ALK* IHC antibodies (using a novel ultrasensitive detection-amplification kit) and an automated *ALK* FISH scanning system (FDA-cleared) in a series of non-small cell lung cancer tumor samples.

Methods: Forty-seven *ALK* FISH-positive and 56 *ALK* FISH-negative NSCLC samples were studied. All specimens were screened for *ALK* expression by two IHC antibodies (clone 5A4 from Novocastra and clone D5F3 from Ventana) and for *ALK* rearrangement by FISH (Vysis *ALK* FISH break-apart kit), which was automatically captured and scored by using Bioview’s automated scanning system.

Results: All positive cases with the IHC antibodies were FISH-positive. There was only one IHC-negative case with both antibodies which showed a FISH-positive result. The overall sensitivity and specificity of the IHC in comparison with FISH were 98% and 100%, respectively.

Conclusions: The specificity of these ultrasensitive IHC assays may obviate the need for FISH confirmation in positive IHC cases. However, the likelihood of false negative IHC results strengthens the case for FISH testing, at least in some situations.

Citation: Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, et al. (2014) Accurate Identification of *ALK* Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence *In Situ* Hybridization Scanning System and Ultrasensitive Immunohistochemistry. PLoS ONE 9(9): e107200. doi:10.1371/journal.pone.0107200

Editor: Renato Franco, Istituto dei tumori Fondazione Pascale, Italy

Received: June 9, 2014; **Accepted:** August 7, 2014; **Published:** September 23, 2014

Copyright: © 2014 Conde et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.

Funding: This work was partially supported by Abbott, Pfizer, Fundación Mutua Madrileña and Fondo de Investigaciones Sanitarias (PI11/02866). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: E. Conde and J. Gómez-Román: honoraria, Pfizer. M. Salido: Advisory Board, Pfizer. E. Arriola: Advisory Board and Research Funding, Pfizer. F. López-Ríos: Advisory Board and Research Funding, Pfizer. Research funding: Abbott and Ventana Medical Systems. Ventana Medical Systems provided reagents free of charge. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

* Email: flopezrios@hmospiales.com

Introduction

In August 2011, crizotinib, a novel *ALK* tyrosine kinase inhibitor, was approved by the US FDA for the treatment of patients with locally advanced or metastatic non-small-cell lung

carcinomas (NSCLCs) that are *ALK*-positive as detected by an FDA-approved test (i.e. Vysis *ALK* FISH Break-Apart Probe Kit) [1]. Soon afterwards, the drug was approved by the EMA, with the statement that “an accurate and validated *ALK* assay is necessary for the selection of patients” [2]. Based on these excellent results of

the crizotinib clinical trials and the development of other *ALK* inhibitors with consistent efficacy results in this patient population, the importance of accurately identifying *ALK* positive lung cancer has never been greater [3].

Few areas in cancer biomarkers have been as contentious as *HER2* testing in breast cancer patients. Since 1998, we have witnessed a huge clinical advance in this field and, however, a great biomarker conundrum over methods, cut-off points, and algorithms [immunohistochemistry (IHC) versus fluorescence *in situ* hybridization (FISH) as the primary testing assay] [4,5]. The outcome is a significant percentage of false negative (12%) or false positive results (14%) [6].

This controversy is also entering the field of NSCLC *ALK* testing [7], with an increasing number of recent publications addressing discordances between *in situ* hybridization and IHC assays [8–14], further fuelled by the different regulatory approvals and the arrival of other *ALK* inhibitors [3,15]. While some groups recommend initial IHC followed by FISH confirmation of some IHC-positive cases [14,16], others believe the detection of *ALK* rearrangements is improved when using two methodologies [9,17]. This situation prompted us to investigate two IHC antibodies, using a novel ultrasensitive detection-amplification kit, and an automated FISH scanning system in a series of tumor samples to obtain supporting data for an *ALK* testing algorithm [18]. To our knowledge, there has not been an independent assessment of *ALK* concordance between these three assays using our strategy (i.e., FDA-cleared automated FISH scanning system) in a large series of *ALK* positive tumors.

Material and Methods

Tumor samples

Seventy-nine *ALK* FISH-positive samples from patients with advanced NSCLCs procured at 11 hospitals were used for this study. The Institutional Ethics Committee at Grupo Hospital de Madrid reviewed and approved this study and waived the need for consent. Samples were consecutive *ALK* positive cases, initially tested as part of routine clinical care. In addition, 77 consecutive *ALK* FISH-negative samples from advanced NSCLCs diagnosed at the referral institution were included as negative controls. The material available for all tumors had been formalin-fixed and paraffin-embedded (FFPE). The specifics of formalin fixation were unknown. All cases were classified by two pathologists (E.C. and F.L.R.) [19,20]. All specimens were independently screened for *ALK* expression by two IHC antibodies, and for *ALK* rearrangement by FISH, which was scored using an automated scanning system (FDA-cleared) [21]. Cases were excluded if we could not score a minimum of 50 nuclei (i.e., gold standard package insert recommendation, see below). The Institutional Ethics Committee at the referral institution reviewed and approved this study.

FISH for *ALK* rearrangement

FISH was performed on unstained 4 μ m-thick FFPE tumor tissue sections using the *ALK* break-apart probe set (Vysis *ALK* FISH break-apart kit; Abbott Molecular, IL, USA), following the manufacturer's instructions [22,23]. The *ALK* FISH assay was independently captured and scored with the automated BioView Duet scanning system (BioView, Rehovot, Israel) by two pathologists blinded to the IHC results (E.C. and A.S-G.). The system included a fluorescent microscope (Olympus), a high-resolution progressive-scan charge-coupled device digital camera, and a computer equipped with imaging and analysis software. The procedure consisted of the following steps: (1) proper tumour tissue sections were selected for automated imaging and analysis using a

$\times 10$ objective to locate the nuclei; (2) the system automatically captured and analyzed the nuclei found in those regions using a $\times 60$ objective with immersion oil and the single band DAPI/SpectrumGreen/SpectrumOrange filter; and (3) the system recorded and classified each target nuclei utilizing a specific algorithm of positive or negative signal patterns based upon the classifications described in the Vysis *ALK* FISH break-apart kit product insert enumeration instructions (also used in the crizotinib clinical trials). Nuclei that the system could not match to defined signal patterns were placed in the unclassified category.

A minimum of 50 tumor nuclei were counted. *ALK* FISH-positive cases were defined as more than 25 (50%) break-apart (BA) signals or an isolated signal (IRS) in tumor cells. *ALK* FISH-negative samples were defined as less than 5 (10%) BA or IRS cells. *ALK* FISH cases were considered borderline if 5–25 (10–50%) cells were positive. In the case of borderline results, a second reader evaluated the slide, added cell count readings from the already automatically captured images, and a percentage was calculated out of 100 cells. If the positive cells percentage was lower than 15%, the sample was considered negative. If the positive cells percentage was higher or equal to 15%, the sample was considered positive (refer to the package insert for Vysis *ALK* Break Apart FISH Probe Kit, Cat. No. 06N38-020/30-608495/R2).

IHC for *ALK* expression

Automated IHC for *ALK* expression was performed for all cases in a Benchmark XT staining module (Ventana Medical Systems, Tucson, AZ). FFPE tumor tissues were sectioned at a thickness of 4 μ m and stained with two different *ALK* antibodies: Ventana anti-*ALK* rabbit monoclonal primary antibody (Clone D5F3, Ventana Medical Systems, Tucson, AZ), and Novocastra mouse monoclonal antibody p80 *ALK* (Clone 5A4, Novocastra, Newcastle, United Kingdom). Briefly, the Ventana anti-*ALK* antibody was applied with OptiView DAB IHC Detection Kit and OptiView Amplification Kit, performing one serial tissue section for Ventana anti-*ALK* (D5F3), and a second serial tissue section for a Rabbit Monoclonal Negative Control Ig antibody, following the manufacturer's instructions. The Novocastra (5A4) antibody was used at 1:20 dilution, treated, and incubated at 37°C for 2 hours. Detection was performed with the same OptiView detection-amplification kit. FISH-validated *ALK*-positive and *ALK*-negative external controls were included in all the slides.

The slides were reviewed by two pathologists (E.C. and F.L.R.) blinded to FISH results. The results of both *ALK* IHC assays were evaluated using a modified H-score: strong cytoplasmic staining (3+), clearly visible using a $\times 2$ or $\times 4$ objective; moderate staining (2+), requiring a $\times 10$ or $\times 20$ objective to be clearly seen; and weak staining (1+), cannot be seen until a $\times 40$ objective is used [21]. Both anti-*ALK* IHC staining results were interpreted using a binary scoring system: positive (3+ or 2+) or negative (1+ or 0), adapting to the manufacturer's instructions [refer to the package insert for Ventana anti-*ALK* (D5F3) Rabbit Monoclonal Primary Antibody, Cat. No. 790-4794/06679072001] and in agreement with recently released survival data in crizotinib treated patients [24].

Statistical data analysis

Based on all the valid data obtained, we performed a descriptive analysis of both the independent and dependent variables of interest. This analysis was stratified by specimen type, location and histologic type. The technique used for comparison of frequencies was Pearson's χ^2 test (frequency < 5 , Fisher). The normality of the continuous variables was verified using the Kolmogorov-Smirnov

Table 1. Concordance between ALK IHC and ALK FISH.

ALK IHC	ALK FISH		FISH-		Total (%)	Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	PPV (%) (95% CI)	NPV (%) (95% CI)	Accuracy (%) (95% CI)
IHC Ventana (D5F3)										
IHC+	3+	46	0	46	46 (44.7)	98 (95–100)	100 (100–100)	100 (100–100)	98 (96–100)	99 (97–100)
	2+	0	0	0						
IHC–	1+	0	8	8	57 (55.3)					
	0	1	48	49						
Total (%)		47 (45.6)	56 (54.4)	103 (100)						
IHC Novocastra (5A4)										
IHC+	3+	41	0	41	46 (44.7)	98 (95–100)	100 (100–100)	100 (100–100)	98 (96–100)	99 (97–100)
	2+	5	0	5						
IHC–	1+	0	0	0	57 (55.3)					
	0	1	56	57						
Total (%)		47 (45.6)	56 (54.4)	103 (100)						

IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value. doi:10.1371/journal.pone.0107200.t001




Figure 1. Study design and specimen selection.
doi:10.1371/journal.pone.0107200.g001

test. As these variables, i.e. number of positive cells and number of negative cells, did not follow a normal distribution, non-parametric tests were used. For comparison of means we used the Kruskal-Wallis test. The sensitivity, specificity, and positive and negative predictive values of the Ventana anti-ALK, Novocastra (5A4), and FISH using an automated scoring system

were obtained. Statistical differences were deemed significant at $p < 0.05$. Statistical data analyses were performed using the Statistical Package for Social Sciences (version 19.0; Chicago, IL, USA).




Figure 2. Immunostaining pattern of ALK in NSCLC using Ventana anti-ALK (D5F3) and Novocastra (5A4) antibodies. ALK IHC reveals variable levels of protein expression: from absent (0) to weak/faint cytoplasmic staining (1+) in negative cases and from moderate (2+) to strong (3+) granular cytoplasmic immunostaining in positive tumors. In ALK IHC-negative cases, the immunoreactivity was always 0 by Novocastra (5A4) IHC, whereas it ranged from 0 to 1+ by Ventana antibody. However, in ALK IHC-positive cases, protein expression was always 3+ by Ventana antibody, whereas it ranged from 2+ to 3+ by Novocastra (5A4) IHC. Original magnification: 400 \times .
doi:10.1371/journal.pone.0107200.g002




Figure 3. Box plots for number of ALK positive cells by FISH automatized technique versus intensity of the ALK IHC staining. With the Ventana anti-ALK antibody (A) and with Novocastra (5A4) antibody (B). Kruskal-Wallis test was performed. The comparisons between the categories in each antibody were statistically significant ($p < 0,001$). doi:10.1371/journal.pone.0107200.g003

Results

The results are summarized in Table 1.

ALK rearrangement assessed by FISH

Of the 79 *ALK*-positive lung carcinoma specimens, 32 cases were excluded for lack of tumor tissue. Of the 77 *ALK*-negative NSCLCs, 21 specimens were excluded for lack of tumor tissue (Figure 1). Among the 103 available cases analyzed, 47 tumors (45.6%) had an *ALK* rearrangement, showing the two major described patterns [BA pattern in 21.3% of cases (10/47), IRS pattern in 44.7% of tumors (21/47), and both patterns in 34% of tumors (16/47)]. Fifty-six (54.4%) cases were negative, showing two fusion signals or very close green and red signals. The total number of tumor cells analyzed was 50 in 98 cases (95.1%) and 100 in 5 specimens (4.9%) (cases with initial borderline results). In *ALK* FISH-negative cases, the mean percentage of positive cancer cells was 0.7% (median 0%; range 0 to 6%). In *ALK* FISH-positive tumors, the mean percentage of positive cells was 68.2% (median 68%; range 25 to 94%). In three of these *ALK*-rearranged cases, the percentage of positive cells was less than 50% (25%, 36% and 46%, respectively). Among FISH *ALK*-positive cases, we observed 5 tumors (10.6%) with *ALK* amplification, as previously described [25].

Correlation between ALK IHC and ALK FISH data

All cases with IHC scores of 3+ (strong cytoplasmic staining) by Ventana anti-*ALK* antibody, and all cases with IHC scores of 2+ and 3+ by Novocastra (5A4) antibody (*ALK* IHC-positive cases) were FISH-positive. All cases but one with IHC scores of 1+ and 0 by Ventana, and with IHC scores of 0 by Novocastra (*ALK* IHC-negative cases) were FISH-negative (Figure 2). There was only one IHC-negative case with both antibodies which showed a FISH-positive result (IRS-rearranged pattern in an average of 84% of tumor cells). Additional blocks were requested and re-tested with identical results (data not shown). Interestingly, it was a surgically resected (lobectomy), poorly differentiated squamous cell carcinoma (SCC) (i.e., p40 positive by IHC, data not shown). Given the discrepancy, all results were independently reviewed (F.L.R.) and confirmed.

ALK immunoreactivity by IHC

Following the above criteria, among the 103 available cases analyzed, 46 cases (44.7%) were positive, whereas 57 tumors (55.3%) were negative by both Ventana anti-*ALK* and Novocastra (5A4) antibodies. Interestingly, in *ALK* IHC-negative cases, the immunoreactivity was always absent (0) by Novocastra (5A4) IHC, whereas it ranged from absent to weak/faint cytoplasmic staining (1+) by Ventana antibody. However, in *ALK* IHC-positive cases, protein expression was always strong cytoplasmic staining (3+) by Ventana anti-*ALK* antibody, whereas it ranged from moderate (2+) (n = 5) to strong staining (3+) (n = 41) by Novocastra (5A4) IHC (Figure 2). In 15 positive cases (32.6%) by Ventana IHC and 16 positive tumors (34.8%) by Novocastra IHC, we noted significant intratumoral heterogeneity, ranging from weak to strong protein expression.

We evaluated the correlation between IHC staining intensity and the number of positive cells by FISH. Increases in the staining intensity by both antibodies were associated with increases in the number of FISH *ALK*-rearranged cells ($p < 0.001$): a staining intensity of 3+ by Ventana IHC resulted in an average of 36.3% FISH *ALK*-positive cells, and a staining intensity of 2+ and 3+ by Novocastra IHC resulted in an average of 31% and 36.9% FISH *ALK*-positive cells, respectively (Figure 3).

Sensitivity and specificity of ALK IHC and ALK FISH

The overall sensitivity and specificity of the IHC in comparison with FISH were 98% and 100%, respectively. The positive and negative predictive value of the IHC was 100% and 98%, respectively.

Correlation between ALK rearrangements and histological data

Among the 47 FISH *ALK*-positive cases, 26 (55.3%) were diagnosed as primary lung origin whereas 21 (44.7%) were metastases from different sites. Of all these samples, nine were bronchoscopic biopsies (19.1%), two core-needle biopsies (4.3%), two cell blocks (4.3%), and 34 surgical resections (72.3%). Interestingly, 50% of the latter were excisions of metastases (n = 17): soft-tissue (n = 10), lymph nodes (n = 6) and ovary (n = 1). Pathological characteristics of the *ALK*-positive tumors were as follows: 43 (91.5%) adenocarcinomas (ACs), one (2.1%) SCC, and three (6.4%) NSCLCs NOS. Among the ACs, a predominant solid and cribriform pattern was observed in 28 out of 43 (65.1%); 11 (25.6%) cases presented acinar architecture; and four (9.3%) a predominant papillary pattern. Signet ring cells were observed in 21 of 43 (48.8%) positive cases, as previously described [26–28].

Discussion

We have studied one of the largest series of *ALK* positive tumors to date. A review of published reports identifies very few larger series of such tumors investigated by more than one methodology, and two of those correspond to surgically treated early stage tumors [11,24,27,29–32]. We find that both IHC and FISH are reasonable approaches for primary routine *ALK* testing, provided that samples have at least 50 informative tumor cells. This is the number of tumor cells that are required for the FDA-approved FISH *ALK* assay. Using this selection criterion, all but one of the FISH positive cases were confirmed with both IHC antibodies. Interestingly, this single IHC false negative result occurred in a patient with a *bona fide* SCC (i.e., lobectomy with a p40 positive tumor by IHC) that had a partial response to crizotinib (data not shown). Although the *ALK* translocation may be found in pure squamous carcinoma of the lung (such as the one reported herein), the role of *ALK* inhibitors in this setting is still controversial [33]. Interestingly, in a recently reported crizotinib phase 3 trial, a very small group of non-adenocarcinoma patients had a remarkable progression-free survival [34]. Taking into consideration the difficulties in determining histologic subtype in small NSCLC biopsies, at present it seems unrealistic to have different *ALK* testing algorithms driven by histology [35]. Nevertheless, histology should always be considered since aberrant *ALK* expression (i.e., rearrangement negative) has been described in neuroendocrine lung carcinomas [17,36].

Although the true reason for the discrepancy outlined above remains unclear, there are two main possible explanations: (a) biological, *ALK* variant-related [12] or due to heterogeneity of staining, as this situation has been reported specially in SCC and adenocarcinoma [13,37]; and, (b) methodological, due to suboptimal pre-analytical or analytical phases as less sensitive detection systems may result in heterogeneous staining patterns [18]. In this regard, FISH is less affected by the unavoidable variability of the pre-analytical phase in pathology laboratories worldwide, as long as buffered formalin is used as the fixative. Along these lines, there is always a risk of IHC false negatives due to the lack of an *in situ* performance control, as opposed to FISH. External positive controls should not be used to distinguish a negative result from a false-negative result caused by uncontrolled

pre-analytical parameters. An interesting comparison can be made with polymerase chain reaction controls. In this methodology, positive control, negative control, water control (equivalent to the negative control in the Ventana assay) and inhibition control or housekeeping gene control (which is lacking in the ALK IHC assays) should be used. Accordingly, we believe that ideally all IHC negative cases should be confirmed by FISH. One may still argue that a single false negative sample is insufficient for this recommendation. However, a careful review of previous studies suggests that our experience is not unique [9,13,17,29,32,38–43]. Remarkably, in some of these studies *ALK* testing was part of routine clinical care, as in our series. A very recent two-site comparison shows around 30% of FISH positive-IHC negative cases [29]. If using this ultrasensitive IHC approach as a screening tool, a practical recommendation would be to confirm by FISH at least some of the negative IHC results (for example, samples with uncontrolled pre-analytical parameters or with higher probability of harboring *ALK* translocations).

Conversely, the specificity of these ultrasensitive IHC assays [14] obviates the need for FISH confirmation in positive IHC cases. In fact, there have been reports of dramatic responses to crizotinib in patients with IHC positive and FISH negative tumors [44]. From a practical point of view, it is important to bear in mind that in many regions of the world the use of *ALK* inhibitors may not be linked to a specific methodology [2]. Taking into consideration the use of improved IHC protocols, eventual false-positive IHC results are more likely to be an interpretative error rather than a technical error, as has been the case in breast *HER2* testing [45]. Because dichotomous scoring has been shown to enhance reproducibility, we must insist in defining such criteria for each clone. For 5A4, any immunostaining was scored as positive. For Ventana, only weak cytoplasmic staining was considered negative (Figure 2). However, several issues may preclude the use of IHC as a final predictive test. Firstly, the common perception that IHC should be used as a screening test, followed by confirmation of the positive cases with the gold-standard method. The proposed algorithm for the use of mutation-specific EGFR IHC has been a step forward for this change of paradigm [46]. Secondly, there is a lack of inter-laboratory and inter-observer uniformity in assay performance and assay interpretation. In this regard, the standardization of the Ventana assay, from both the analytical and post-analytical point of view, can help implement this strategy. Our results with the Novocastra antibody and the ultrasensitive IHC protocol are very similar to those of other groups [47].

Finally, it must be emphasized that we (E.C, unpublished data) and others [14,48,49] have found positive ALK IHC particularly useful in limited samples or when FISH is not evaluable. However, a broadly held consensus on the number of positive cells required for an IHC positive score has yet to emerge. Indeed, it has been shown that, when less than 50 tumor cells are present, there is a risk for false-negative IHC results [9]. Accordingly, the number of IHC positive cells has been compared with staining intensity, for example, a staining intensity of 2+ required 58.2% of positively stained cells [50]. The significant correlation that we found when we compared the number of FISH positive cells and the IHC intensity further supports the validity of our data.

Due to a series of factors which often coexist, it is difficult to apply the findings of *ALK* testing published in the literature to the

clinical reality. Outside of clinical trials or referral testing laboratories [29,34,51], most series mainly test surgically resected specimens or tissue microarrays [11–13,16,27,50,52–59] rather than small biopsies with intention to treat [9,14,30,31,38,60–62]. Therefore, one of the strengths of this study is that this large cohort of *ALK* positive samples was initially tested with intention to treat. However, the fact that over 72% of the samples were “large” specimens (50% of them surgically resected metastases) is a minor limitation of our series and may not represent routine clinical practice. Moreover, we had very few cytology samples which are the most common form of diagnostic material in many institutions. Although recently released guidelines [35] recommend the use of cell blocks, excellent results have been reported for both IHC and FISH with stained smears and liquid-based preparations [14,38,63]. Another potential caveat of our work is that this is a retrospective series and we cannot comment on the performance of the assays in predicting response to *ALK* inhibition. To partially overcome this shortcoming, we decided to increase the robustness of the gold standard. Reasoning that the *ALK* FISH assay is especially difficult to interpret and prone to both false-negatives and false-positives [9,14,32,38,49,59,64], we used an outstanding automated FISH scanning system that has recently received FDA-clearance. This strategy provided fast automated scanning, which reduced overall scoring and reporting time, provided standardization of the FISH signal interpretation and ensured sensitive counting.

In summary, we find that IHC and FISH techniques are optimal for the detection of *ALK* translocations in NSCLC patients if at least 50 tumor cells are scored and protocols are strictly followed. The interpretative stringency provided by using negative controls and knowledge of interpretation patterns can avoid IHC false positive cases. The real-world likelihood of false negative IHC results, whether biological or methodological, strengthens the case for FISH confirmation, at least in some situations (for example, in samples with uncontrolled pre-analytical parameters or with higher probability of harboring *ALK* translocations). A consideration of the clinical problem of NSCLC highlights the need to be aware of how the methods that we use perform in reality.

Acknowledgments

F. López-Ríos thanks R. Franklin for her contribution to this work. The authors wish to thank the Tumor Bank at the ‘Laboratorio de Dianas Terapéuticas’, Hospital Universitario Sanchinarro, for handling the samples used in this study, and Dr. Lukas Bubendorf (Basel) for his help with the immunohistochemistry protocols. The excellent technical help of Luna Muñoz is also gratefully acknowledged. Translated into English by Michelle Homden.

Author Contributions

Conceived and designed the experiments: EC FL-R. Performed the experiments: EC FL-R AS-G. Analyzed the data: EC AS-G AB PG RG-C MB LP-A DH JC MCC DR-A IA JR NR MS LP EA JS VF NV JG-R MH FL-R. Contributed reagents/materials/analysis tools: EC AS-G AB PG RG-C MB LP-A DH JC MCC DR-A IA JR NR MS LP EA JS VF NV JG-R MH FL-R. Wrote the paper: EC AS-G AB PG RG-C MB LP-A DH JC MCC DR-A IA JR NR MS LP EA JS VF NV JG-R MH FL-R.

References

- Riely GJ, Chaft JE, Ladanyi M, Kris MG (2011) Incorporation of crizotinib into de NCCN guidelines. *J Natl Compr Can Netw* 9: 1328–1330.
- European Medicines Agency. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002489/WC500134761.pdf. Accessed 2013 July 21.

3. Gridelli C, Solange P, Sgambato A, Casaluca F, Adjei AA, et al. (2014) ALK inhibitors in the treatment of advanced NSCLC. *Cancer Treat Rev* 40: 300–306.
4. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, et al. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol* 31: 3997–4013.
5. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. *J Clin Oncol* 27: 1323–1333.
6. De P, Smith BR, Leyland-Jones B (2010) Human epidermal growth factor receptor 2 testing: where are we? *J Clin Oncol* 28: 4289–4292.
7. Karachaliou N, Rosell R (2013) Optimal detection of ALK rearranged lung adenocarcinomas. *J Thorac Oncol* 8: 255–256.
8. Kim H, Xu X, Yoo SB, Sun PL, Jin Y, et al. (2013) Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases. *Histopathology* 62: 305–314.
9. Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, et al. (2013) Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. *J Thorac Oncol* 8: 322–328.
10. Han XH, Zhang NN, Ma L, Lin DM, Hao XZ, et al. (2013) Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. *Virchows Arch* 463: 583–591.
11. Ying J, Guo L, Qiu T, Shan L, Ling Y, et al. (2013) Diagnostic value of a novel fully automated immunohistochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. *Ann Oncol* 24: 2589–2593.
12. Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, et al. (2013) Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan. *PLoS One* 8: e70839.
13. Li Y, Pan Y, Wang R, Sun Y, Hu H, et al. (2013) ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR. *PLoS One* 8: e69016.
14. Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, et al. (2013) ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. *J Mol Diagn* 15: 341–346.
15. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, et al. (2014) Crizotinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med* 370: 1189–1197.
16. Takamochi K, Takeuchi K, Hayashi T, Oh S, Suzuki K (2013) A Rational Diagnostic Algorithm for the Identification of ALK Rearrangement in Lung Cancer: A Comprehensive Study of Surgically Treated Japanese Patients. *PLoS One* 8: e69794.
17. Murakami Y, Mitsudomi T, Yatabe Y (2012) A Screening Method for the ALK Fusion Gene in NSCLC. *Front Oncol* 2: 1–9.
18. Nitta H, Tsuta K, Yoshida A, Ho SN, Kelly BD, et al. (2013) New Methods for ALK Status Diagnosis in Non-Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC-In Situ Hybridization Assay. *J Thorac Oncol* 8: 1019–1031.
19. Travis WD, Brambilla E, Müller-Hermelink HK, Curtis CH (2004) WHO Classification. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press.
20. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 6: 244–285.
21. BioView. Available: http://www.bioview.co.il/HTMLs/page_70.aspx?c0=12677&bsp=12624&bs53=12640. Accessed 2014 May 14.
22. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, et al. (2012) EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. *Virchows Arch* 461: 245–257.
23. Conde E, Angulo B, Izquierdo E, Muñoz L, Suárez-Gauthier A, et al. (2013) The ALK translocation in advanced non-small-cell lung carcinomas: pre-approval testing experience at a single cancer centre. *Histopathology* 62: 609–616.
24. Zhang NN, Liu YT, Ma L, Wang L, Hao XZ, et al. (2014) The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. *PLoS One* 9: e84501.
25. Salido M, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, et al. (2011) Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. *J Thorac Oncol* 6: 21–27.
26. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. *Clin Cancer Res* 15: 5216–5223.
27. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, et al. (2011) Comprehensive histologic analysis of ALK-rearranged lung carcinomas. *Am J Surg Pathol* 35: 1226–1234.
28. Nishino M, Klepeis VE, Yeap BY, Bergthoff K, Morales-Oyarvide V, et al. (2012) Histologic and cytomorphic features of ALK-rearranged lung adenocarcinomas. *Mod Pathol* 25: 1462–1472.
29. Cabillio F, Gros A, Dugay F, Begueret H, Mesturoux L, et al. (2014) Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances. *J Thorac Oncol* 9: 295–306.
30. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, et al. (2013) ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. *Clin Cancer Res* 19: 4273–4281.
31. Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, et al. (2014) Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation. *Clin Cancer Res* 20: 1383–1392.
32. Wynes MW, Sholl LM, Dietel M, Schuurings E, Tsao MS, et al. (2014) An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. *J Thorac Oncol* 9: 631–638.
33. Caliò A, Nottage A, Gilioli E, Bria E, Pilotto S, et al. (2014) ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. *J Thorac Oncol* 9: 729–732.
34. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 368: 2385–2394.
35. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Arch Pathol Lab Med* 137: 828–860.
36. Nakamura H, Tsuta K, Yoshida A, Shibata T, Wakai S, et al. (2013) Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. *J Clin Pathol* 66: 705–706.
37. Takeuchi K (2013) Interpretation of Anti-ALK Immunohistochemistry Results. *J Thorac Oncol* 8: e67–e68.
38. Savic S, Bode B, Diebold J, Tosoni I, Barascud A, et al. (2013) Detection of ALK-Positive Non-Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone. *J Thorac Oncol* 8: 1004–1011.
39. Martínez P, Hernández-Losa J, Montero MÁ, Cedrés S, Castellví J, et al. (2013) Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. *PLoS One* 8: e52261.
40. Blackhall FH, Peters S, Kerr KM, O'Byrne KJ, Hager H, et al. (2012) Prevalence and clinical outcomes for patients with ALK positive adenocarcinoma in Europe: preliminary results from the European Thoracic Oncology Platform Lungscape Project. *ESMO*.
41. Le Quesne J, Maurya M, Yancheva SG, O'Brien M, Popat S, et al. (2014) A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material. *J Thorac Oncol* 9: 769–774.
42. Demidova I, Barinov A, Savelov N, Gagarin I, Grinevich V, et al. (2014) Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. *Arch Pathol Lab Med* 138: 794–802.
43. Ali G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, et al. (2014) ALK Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescent In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. *Arch Pathol Lab Med Jun 2*. [Epub ahead of print] PubMed PMID: 24885803.
44. Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, et al. (2012). A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. *J Thorac Oncol* 7: e36–38.
45. Grimm EE, Schmidt RA, Swanson PE, Dintzis SM, Allison KH (2010) Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. *Am J Clin Pathol* 134: 284–292.
46. Brevet M, Arcila M, Ladanyi M (2010) Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. *J Mol Diagn* 12: 169–176.
47. Tuononen K, Sarhadi VK, Wirtanen A, Rönty M, Salmenkivi K, et al. (2013) Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. *Biomed Res Int* 757490.
48. Dacic S (2013) Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. *J Clin Pathol* 66: 870–874.
49. Zhou J, Zhao J, Sun K, Wang B, Wang L, et al. (2014) Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening. *PLoS One* 9: e92828.
50. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, et al. (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. *J Thorac Oncol* 6: 466–472.
51. McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, et al. (2012) Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. *J Thorac Oncol* 7: 348–354.
52. Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, et al. (2012) Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. *Lung Cancer* 77: 319–325.

53. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, et al. (2012) Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. *Lung Cancer* 76: 403–409.
54. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer* 115: 1723–1733.
55. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. *Mod Pathol* 22: 508–515.
56. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, et al. (2013) Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. *J Thorac Oncol* 8: 45–51.
57. Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P et al. (2013) Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. *Mod Pathol* 26: 1545–1553.
58. V Laffert M, Warth A, Penzel R, Schirmacher P, Jonigk D, et al. (2013) Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing. *Lung Cancer* 81: 200–206.
59. To KF, Tong JH, Yeung KS, Lung RW, Law PP et al. (2013) Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant. *J Thorac Oncol* 8: 883–891.
60. Li T, Maus MK, Desai SJ, Beckett LA, Stephens C, et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. *J Thorac Oncol* 9: 18–25.
61. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, et al. (2013) Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. *Ann Oncol* 24: 59–66.
62. Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, et al. (2013) Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: Implications for ALK inhibitor therapy. *Cancer* 119: 3968–3975.
63. Proietti A, Ali G, Pelliccioni S, Lupi C, Sensi E, et al. (2014) Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: Comparison with histological assessment. *Cancer Cytopathol*. 122: 445–453.
64. Wallander ML, Geiersbach KB, Tripp SR, Layfield IJ (2012) Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. *Arch Pathol Lab Med* 136: 796–803.